Biotech investors should keep a close eye on the progress in this huge potential market.
Pet costs are seen surging, as are several other top household categories.
Financial names populate the bullish side.
The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.